Alcresta Therapeutics

Executive Summary

Alcresta Therapeutics is a private biotechnology company focused on developing novel enzyme-based products to improve nutritional care for patients with rare diseases requiring enteral nutrition. Its flagship product, RELiZORB, is a digestive enzyme cartridge that addresses fat malabsorption in enterally fed patients by delivering lipase directly into the feeding tube. RELiZORB has received FDA clearance for use in pediatric and adult patients, providing a unique solution to improve fat absorption and growth in this vulnerable population. The company is also exploring expanded indications and next-generation enzyme formulations to address unmet needs in metabolic and gastrointestinal disorders. Despite its commercial product, Alcresta remains private and continues to invest in clinical development and pipeline expansion. With a focused strategy on niche rare disease markets and established regulatory approvals, Alcresta is positioned for steady growth but faces challenges in scaling commercialization and advancing earlier-stage programs.

Upcoming Catalysts (preview)

• Q4 2026New clinical data for RELiZORB in expanded pediatric or adult populations70% success
• 2027Partnership or licensing deal for pipeline candidates (e.g., ALP-001 or next-gen enzymes)50% success
• 2027Series D or later-stage financing round to support commercialization and R&D60% success